MX2016002397A - Union de polipeptidos estables al componente 5(c5) de complemento humano. - Google Patents

Union de polipeptidos estables al componente 5(c5) de complemento humano.

Info

Publication number
MX2016002397A
MX2016002397A MX2016002397A MX2016002397A MX2016002397A MX 2016002397 A MX2016002397 A MX 2016002397A MX 2016002397 A MX2016002397 A MX 2016002397A MX 2016002397 A MX2016002397 A MX 2016002397A MX 2016002397 A MX2016002397 A MX 2016002397A
Authority
MX
Mexico
Prior art keywords
human complement
polypeptides binding
stable polypeptides
stable
binding
Prior art date
Application number
MX2016002397A
Other languages
English (en)
Inventor
Nordling Erik
Nilsson Joakim
Strömberg Patrik
Original Assignee
Swedish Orphan Biovitrum Ab (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab (Publ) filed Critical Swedish Orphan Biovitrum Ab (Publ)
Publication of MX2016002397A publication Critical patent/MX2016002397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a un polipéptido capaz de unirse al componente del complemento humano 5 (C5), tal polipéptido que comprende la secuencia de aminoácido [BM]-[L2]-QSX42X43LLX46EAKKLX 52X53X54Q en donde [BM] es un motivo de unión a C5; [L2] es un bucle de interconexión; X42 se selecciona de A y S; X43 se selecciona de N y E; X46 se selecciona de A, S y C; X52 se selecciona de E, N y S; X53 se selecciona de D, E y S, siempre que X53 no sea D cuando X52 es N; y X54 se selecciona de A y S.
MX2016002397A 2013-08-28 2014-08-28 Union de polipeptidos estables al componente 5(c5) de complemento humano. MX2016002397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
MX2016002397A true MX2016002397A (es) 2016-09-08

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002397A MX2016002397A (es) 2013-08-28 2014-08-28 Union de polipeptidos estables al componente 5(c5) de complemento humano.

Country Status (29)

Country Link
US (1) US9994626B2 (es)
EP (2) EP3811961A1 (es)
JP (2) JP6767865B2 (es)
KR (1) KR102446636B1 (es)
CN (1) CN105658228B (es)
AU (1) AU2014314222B2 (es)
BR (2) BR122023020080A2 (es)
CA (1) CA2926976C (es)
CY (1) CY1123732T1 (es)
DK (1) DK3038633T3 (es)
ES (1) ES2842105T3 (es)
HK (1) HK1225656A1 (es)
HR (1) HRP20210013T1 (es)
HU (1) HUE052613T2 (es)
IL (1) IL244218A (es)
LT (1) LT3038633T (es)
MX (1) MX2016002397A (es)
MY (1) MY173804A (es)
NZ (1) NZ718153A (es)
PH (1) PH12016500371B1 (es)
PL (1) PL3038633T3 (es)
PT (1) PT3038633T (es)
RS (1) RS61347B1 (es)
RU (2) RU2020128977A (es)
SA (1) SA516370622B1 (es)
SG (1) SG11201602679VA (es)
SI (1) SI3038633T1 (es)
UA (1) UA117933C2 (es)
WO (1) WO2015028558A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2817329T (pt) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
CA2920005C (en) * 2013-08-28 2023-11-28 Affibody Ab Binding polypeptides having a mutated scaffold
BR122023020080A2 (pt) * 2013-08-28 2023-12-26 Swedish Orphan Biovitrum Ab (Publ) Ligação de polipeptídeos estáveis ao c5 do complemento humano
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
AU2018301412A1 (en) 2017-07-11 2020-01-30 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
CA3237246A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP3031827A1 (en) 2000-10-10 2016-06-15 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
ES2562423T3 (es) * 2006-03-08 2016-03-04 Archemix Llc Aptámeros de unión a complemento y agentes anti-C5 útiles para el tratamiento de trastornos oculares
BR122017024057B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
CN104710518A (zh) 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
WO2009077175A1 (en) * 2007-12-19 2009-06-25 Affibody Ab Polypeptide derived from protein a and able to bind pdgf
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
ES2541142T3 (es) 2008-08-05 2015-07-16 Novartis Ag Composiciones y métodos para anticuerpos dirigidos contra la proteína C5 del complemento
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
PT2817329T (pt) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
WO2014096163A1 (en) 2012-12-19 2014-06-26 Affibody Ab New polypeptides
CA2920005C (en) 2013-08-28 2023-11-28 Affibody Ab Binding polypeptides having a mutated scaffold
BR122023020080A2 (pt) * 2013-08-28 2023-12-26 Swedish Orphan Biovitrum Ab (Publ) Ligação de polipeptídeos estáveis ao c5 do complemento humano

Also Published As

Publication number Publication date
CN105658228B (zh) 2020-02-07
BR122023020080A2 (pt) 2023-12-26
JP2016529270A (ja) 2016-09-23
AU2014314222A1 (en) 2016-04-21
HK1225656A1 (zh) 2017-09-15
UA117933C2 (uk) 2018-10-25
RU2733897C2 (ru) 2020-10-09
EP3811961A1 (en) 2021-04-28
US20160311870A1 (en) 2016-10-27
PT3038633T (pt) 2021-01-14
EP3038633A1 (en) 2016-07-06
IL244218A (en) 2017-11-30
WO2015028558A1 (en) 2015-03-05
SI3038633T1 (sl) 2021-05-31
IL244218A0 (en) 2016-04-21
CY1123732T1 (el) 2021-10-29
KR20160048121A (ko) 2016-05-03
RU2020128977A (ru) 2021-11-30
SG11201602679VA (en) 2016-05-30
HUE052613T2 (hu) 2021-05-28
PH12016500371A1 (en) 2016-05-02
KR102446636B1 (ko) 2022-09-23
EP3038633B1 (en) 2020-10-14
DK3038633T3 (da) 2021-01-11
RS61347B1 (sr) 2021-02-26
PH12016500371B1 (en) 2016-05-02
CA2926976C (en) 2023-11-28
US9994626B2 (en) 2018-06-12
PL3038633T3 (pl) 2021-07-19
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
RU2016111115A3 (es) 2018-04-25
RU2016111115A (ru) 2017-10-03
LT3038633T (lt) 2021-03-25
NZ718153A (en) 2022-05-27
SA516370622B1 (ar) 2018-12-23
CN105658228A (zh) 2016-06-08
CA2926976A1 (en) 2015-03-05
JP6767865B2 (ja) 2020-10-14
JP2020172505A (ja) 2020-10-22
MY173804A (en) 2020-02-24
ES2842105T3 (es) 2021-07-12
HRP20210013T1 (hr) 2021-04-02

Similar Documents

Publication Publication Date Title
PH12016500371A1 (en) Stable polypeptides binding to human complement c5
WO2018083087A3 (en) Binding proteins
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2019011952A (es) Proteina anti-garp y sus usos.
PH12017501863A1 (en) Bioconjugates and uses thereof
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
EP3957723A3 (en) Engineered ligase variants
TWD189012S (zh) 針盤
NZ732978A (en) Il-17a-binding polypeptides
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
WO2016023898A3 (en) Intracellular antigen binding
TWD189226S (zh) 針盤
MX2019008722A (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
EA201591421A1 (ru) Препараты полипептида фактора ix
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
EP3681911A4 (en) HUMAN THROMBIN RECEPTOR BIND PROTEINS, PAR4
EP4403566A3 (en) Peptides with vasodilatory and/or diuretic functions